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ABSTRACT
Everolimus inhibits mTOR kinase activity and its downstream targets by 
acting on mTORC1 and has anti-tumorigenic activity in ovarian cancer. Clinical and 
epidemiologic data find that obesity is associated with worse outcomes in ovarian 
cancer. In addition, obesity leads to hyperactivation of the mTOR pathway in epithelial 
tissues, suggesting that mTOR inhibitors may be a logical choice for treatment in 
obesity-driven cancers. However, it remains unclear if obesity impacts the effect 
of everolimus on tumor growth in ovarian cancer. The present study was aimed at 
evaluating the effects of everolimus on cytotoxicity, cell metabolism, apoptosis, cell 
cycle, cell stress and invasion in human ovarian cancer cells. A genetically engineered 
mouse model of serous ovarian cancer fed a high fat diet or low fat diet allowed 
further investigation into the inter-relationship between everolimus and obesity 
in vivo. Everolimus significantly inhibited cellular proliferation, induced cell cycle G1 
arrest and apoptosis, reduced invasion and caused cellular stress via inhibition of 
mTOR pathways in vitro. Hypoglycemic conditions enhanced the sensitivity of cells to 
everolimus through the disruption of glycolysis. Moreover, everolimus was found to 
inhibit ovarian tumor growth in both obese and lean mice. This reduction coincided 
with a decrease in expression of Ki-67 and phosphorylated-S6, as well as an increase 
in cleaved caspase 3 and phosphorylated-AKT. Metabolite profiling revealed that 
everolimus was able to alter tumor metabolism through different metabolic pathways 
in the obese and lean mice. Our findings support that everolimus may be a promising 
therapeutic agent for obesity-driven ovarian cancers. 
INTRODUCTION
Ovarian cancer is the most lethal gynecologic 
malignancy among women, with an anticipated 
21,290 new cases and 14,180 deaths anticipated for 
2015 in the United States [1]. Due to the lack of an 
effective method for the early detection of this disease, 
most ovarian cancer cases are diagnosed at advanced 
stages with a survival rate of less than 40% at 5 years 
[2]. The standard treatment of ovarian cancer is surgical 
debulking combined with platinum-based combination 
chemotherapy. Although this therapeutic strategy has 
high initial response rates, the majority of patients are 
ultimately faced with a recurrence and chemoresistant 
disease [3]. Thus, there is a clear need for additional 
therapeutic options for this deadly disease. 
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Accumulating epidemiological evidence shows that 
obesity is associated with an increased risk of developing 
ovarian cancer compared with women of normal weight 
[4]. Obesity also confers an increased risk of recurrence, 
challenges with chemotherapy dosing, and associated poor 
survival. This results in a 10–17% reduction in overall 
survival among obese women with ovarian cancer [4–6]. 
Several mechanisms have been proposed to underlie 
the relationship between obesity and cancer. Obesity 
provides a unique adipose tissue microenvironment with 
concomitant systemic endocrine alterations that favor both 
carcinogenesis and progression [7]. Elevated levels of sex 
steroids, activation of the insulin–IGF-1 axis, aberrant 
productions of adipokines and inflammatory cytokines 
have all been found to cause tumor growth through 
activation of the PI3K/AKT/mTOR pathway, including 
that of ovarian cancers [4, 7, 8]. We have recently 
found that obesity promotes tumor aggressiveness in a 
genetically engineered mouse model of serous ovarian 
cancer [9]. 
Increased activation of the PI3K/AKT/mTOR 
signaling pathway as a central regulator of proliferation 
and metabolism has been implicated in diabetes, obesity 
and cancer [10]. Amplification of PIK3CA has been 
observed in approximately 40% of ovarian cancers, and 
somatic PIK3CA mutations are detected in 18% of ovarian 
cancers [11, 12]. Phosphorylation of mTOR expression 
has been found in 55% of ovarian cancers, and high levels 
of mTOR signaling have been found to be an independent 
biomarker of poor survival in epithelial ovarian cancer 
[13, 14]. Moreover, simultaneous AKT and mTOR 
activation can be present in up to 87% of ovarian tumors 
[15]. Thus, targeting the PI3K/AKT/mTOR pathway could 
have a potential role in the treatment of ovarian cancer, 
particularly for tumors in obese women. 
The activation of the mTOR pathway is carried 
out by two distinct complexes: mTORC1 and mTORC2. 
mTORC1 is a major downstream target of the PI3K/
AKT pathway. It activates protein synthesis by 
phosphorylating key regulators of messenger RNA 
translation and ribosome synthesis, which controls 
the translation of key regulatory proteins [16, 17]. 
Everolimus is a rapamycin derivative that inhibits 
the mTOR kinase activity and downstream pathways 
by acting on mTORC1. It binds to FK506-binding 
protein-12 forming an inhibitory complex with mTORC1 
[18]. The FDA currently has approved everolimus to treat 
patients with metastatic renal cell carcinoma, advanced 
pancreatic neuroendocrine tumors and advanced 
hormone receptor-positive breast cancer [18]. Given that 
the PI3K/AKT/mTOR pathway is frequently activated in 
ovarian cancer and obesity, this study aimed to access 
the anti-tumorigenic efficacy of everolimus in ovarian 
cancer cells under different glucose conditions in vitro 
and in lean and obese mouse models of serous ovarian 
cancer in vivo. 
RESULTS
Everolimus inhibits cell proliferation and colony 
formation in ovarian cancer cells
The effect of everolimus on growth inhibition was 
examined in the HEY, SKOV3, OVCAR5, IGROV1 and 
OV433 cell lines. Using these cell lines, we first examined 
cell proliferation via MTT assay in vitro following 
72 hours of exposure to varying doses of everolimus. 
As shown in Figure 1A, everolimus inhibited cell 
proliferation in a dose-dependent manner in all five cell 
lines. We found that everolimus inhibited cell growth even 
at low doses after 72 hours of treatment, with a mean IC50 
between 10 uM to 18 uM. In vitro colony formation assays 
are excellent indicators of long term tumor cell survival 
and enable predictions of the long term anti-tumor effects 
of drugs. Given this, we explored whether everolimus had 
an effect on colonization in the SKOV3 and OVCAR5 cell 
lines. The results showed that clonogenicity of both cell 
lines was reduced in a concentration-dependent manner 
after exposure to everolimus (1 and 100 nM) for 10 days 
(p < 0.05) (Figure 1B). 
To further determine the clinical relevance of 
everolimus treatment, we evaluated the effect of this drug 
in primary cultures of human ovarian cancer. Ten tissue 
samples were obtained from patients undergoing surgery 
for primary epithelial serous ovarian cancer. The primary 
culture cells were treated with everolimus at varying doses 
for 72 hours. MTT assays showed that all primary cultures 
responded to the everolimus treatment with growth 
inhibition, as seen in the five established ovarian cancer 
cell lines. None of the primary culture assays reached the 
point of 50% inhibition at a maximum everolimus dose of 
500 nM. Together, these results suggest that everolimus 
effectively inhibits cell proliferation in ovarian cancer 
cells in vitro.
Everolimus induces cell cycle G1 arrest and 
apoptosis in ovarian cancer cells
To evaluate the underlying mechanism of growth 
inhibition by everolimus, the cell cycle profile was 
analyzed after treating SKOV3 and OVCAR5 cells 
with varying doses (10, 100, 500 nM) of everolimus for 
24 hours. As shown in Figure 2A, everolimus treatment 
resulted in cell cycle G1 phase arrest in a dose-dependent 
manner in both the cell lines when compared with the 
control groups (p < 0.05). To further understand the 
molecular events underlying the observed G1 arrest, we 
observed the effects of everolimus on key checkpoint 
molecules. Everolimus decreased expression of CDK6 and 
cyclin D1 and increased expression of p21 in both cell 
lines after 24 hours of treatment (Figure 2C), suggesting 
that everolimus induces growth inhibition through 
induction of G1 phase arrest in ovarian cancer cells. 
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In order to determine whether the reduction of cell 
viability was due to apoptosis, we detected apoptotic cells 
by applying an Annexin-V and PI double staining assay 
using Cellometer. As shown in Figure 2B, everolimus 
significantly increased Annexin V positive cells of SKOV3 
and OVCAR5 in a dose-dependent manner after 24 hours 
of treatment when compared to the control. In the SKOV3 
cells, early apoptosis increased from 8% in control cells 
to 14.5% in cells treated with everolimus at a dose of 
500 nM (p = 0.0001). In the OVCAR5 cells, treatment 
with everolimus enhanced early apoptosis from 6.7% 
in controls to 12.5% at a dose of 500 nM (p = 0.0009). 
We also found that everolimus reduced protein expression 
of BCL-2 and MCL-1 in a dose-dependent manner in both 
cells after treatment for 24 hours (Figure 2D). Together, 
these results suggest that everolimus not only induces G1 
arrest but also causes apoptosis in ovarian cancer cells. 
Everolimus induces cell stress in ovarian cancer 
cells
Given that mTOR activity is strongly stimulated 
by oxidative stress and inhibited by antioxidants [19], we 
next investigated the effect of everolimus on induction of 
cellular stress. We examined the reactive oxygen species 
(ROS) level and protein expression of cellular stress in 
both the SKOV3 and OVCAR5 cell lines after treatment 
with everolimus for 24 hours. Everolimus significantly 
increased ROS levels in both cell lines in a dose-dependent 
fashion (p < 0.05) (Figure 3A). ROS levels were increased 
by 14–16% in SKOV3 and OVCAR5 cells at a dose of 
500 nM, respectively. Western blotting showed that 
everolimus also increased the expression of Bip, PREK 
and Calnexin in a dose-dependent manner after 24 hours 
of treatment, indicating the cells were under stress 
(Figure 3B). These results suggest that an increase in ROS 
production might also be involved in the anti-tumorigenic 
effects of everolimus in ovarian cancer cells.
Everolimus inhibits mTOR pathway in ovarian 
cancer cells
To evaluate the effect of everolimus on the mTOR 
pathway, we treated SKOV3 and OVCAR5 cells with 
various doses of everolimus for 24 hours. The results 
showed that phosphorylation of S6 was significantly 
decreased by everolimus treatment in a dose-dependent 
fashion in both cell lines, suggesting inhibition of 
downstream signaling targets of mTOR. Because 
everolimus is a specific inhibitor of the mTORC1 
protein complex and mTORC1 inhibition disrupts 
the negative feedback loop mediated by PI3K/AKT/
mTOR, we assessed changes in phosphorylation of AKT 
after treatment. As shown in Figure 4, treatment with 
Figure 1: Everolimus suppressed cell proliferation and colony formation. The ovarian cancer cell lines, HEY, SKOV3, 
OVCAR5, IGROV1 and OV433, were cultured for 24 h and then treated with varying concentration of everolimus (from 10 to 25000 nM) 
in 96 well plates for 72 h. Cell proliferation was assessed by MTT assay (A). The effect of everolimus on long term growth in SKOV3 and 
OVCAR5 was assessed through a colony-forming assay (B). Ten primary cultures of human ovarian cancers were cultured for 24 h and 
treated with everolimus at 10 to 500 nM for 72 h. MTT showed that everolimus decreased cell proliferation in primary cultures of ovarian 
cancer (C). *p < 0.05, **p < 0.01.
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everolimus effectively increased the phosphorylation 
of AKT at Thr 308 in both cells and AKT at Ser 473 in 
SKOV3 cells, indicating that inhibition of mTORC1 by 
everolimus resulted in an accumulation of phosphorylated 
AKT activity through a negative feedback loop. 
Phosphorylation of AKT at Ser 473 was decreased in a 
dose-dependent manner in OVCAR5 cells in response to 
everolimus treatment, which suggests everolimus inhibited 
mTOR signaling through both mTORC1 and mTORC2 
signaling pathways in OVCAR5 cells. Our results find that 
mTORC1 inhibition by everolimus potentially triggers a 
negative feedback mechanism, and that everolimus may 
have a function in targeting of mTORC2 complex in 
ovarian cancer cells [20].
Glucose affects the sensitivity to everolimus in 
ovarian cancer cells
Everolimus has been reported to reduce glucose 
uptake in vivo [21–23]. Thus, we examined whether 
different glucose concentrations influence the effects of 
everolimus on cell growth in ovarian cancer cells. SKOV3 
and OVCAR5 cells were cultured in 96-well plates in 
their regular media with 25 mM glucose (hyperglycemic 
condition, HG), 5 mM glucose (euglycemia, NG) and 
1 mM glucose (hypoglycemic condition, LG) and then 
the cells were treated with increasing concentrations 
of everolimus (from 10 to 500 nM) for 48 hours. MTT 
results showed that everolimus slightly inhibited cell 
proliferation in the hyperglycemic condition compared 
with euglycemia. In contrast, everolimus significantly 
inhibited cell proliferation in a dose-dependent manner 
under hypoglycemic conditions in comparison with 
euglycemic and hyperglycemic conditions (Figure 5A), 
suggesting that glucose concentration has the ability to 
affect the sensitivity to everolimus. We next examined 
the effects of everolimus on S6 protein expression under 
different concentrations of glucose. The results showed 
that hyperglycemia caused a three to four fold increase 
in S6 phosphorylation in both cells compared with 
hypoglycemia and euglycemia for 24 hours. Everolimus 
caused a more marked decrease in S6 phosphorylation in 
euglycemic and hypoglycemic conditions as compared 
to hyperglycemic conditions (Figure 5B). Everolimus 
exhibited a significant decrease in inhibition of mTOR/S6 
activity for the cells incubated under the hyperglycemic 
condition, indicating that phosphorylation of S6 may 
be involved in sensitivity to everolimus under different 
glucose conditions in ovarian cancer cells. 
The effect of everolimus on G1 phase arrest and 
apoptosis via was further assessed in varying glucose 
conditions. Incubation of the cells under hypoglycemic 
conditions for 24 hours increased G1 phase cell cycle 
arrest from 59% to 65% in SKOV3 cells, and from 67% 
Figure 2: Everolimus induced cell cycle G1 arrest and cellular apoptosis. The SKOV3 and OVCAR5 cells were cultured for 
24 h and then treated with everolimus at varying doses (from 10 to 500 nM) for 48 h. Cell cycle was examined by Cellometer. Everolimus 
induced cell cycle G1 arrest in a dose-dependent manner in both cell lines (A). The SKOV3 and OVCAR5 cells were treated with varying 
doses of everolimus for 24 h, and cell apoptosis was examined by an Annexin-V and PI double staining assay via Cellometer. Everolimus 
significantly increased cell apoptosis in a dose-dependent manner in both cells (B). The cells were treated with various concentrations 
of everolimus as indicated (from 10 to 500 nM) for 24 h, and the expression of cell cycle proteins were assessed using western blotting 
analysis. Everolimus decreased the levels of cyclin D1 and CDK6 and increased the expression of p21 in the SKOV3 and OVCAR5 cell 
lines (C). The protein expression of Mcl-1 and Bcl-2 was decreased after 24 h of treatment with the indicated doses of everolimus in the 
SKOV3 and OVCAR5 cells (D). *p < 0.05, **p < 0.01.
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Figure 3: Everolimus induced cell oxidative stress in ovarian cancer cells. The SKOV3 and OVCAR5 cells were cultured 
for 24 h and treated with everolimus at 10 to 500 nM doses for 12 h. ROS production was tested using the DCFH-DA assay. Everolimus 
increased the ROS level in a dose-dependent manner in the SKOV3 and OVCAR5 cells after 12 h of treatment (A). The cells were treated 
with various concentrations of everolimus for 6 h. Western blotting showed that everolimus increased the expression of stress proteins 
(PERK, BIP and CALNEXIN) in the SKOV3 and OVCAR5 cell lines (B). *p < 0.05.
Figure 4: The effect of everolimus on the AKT/mTOR pathway in ovarian cancer cell lines. The SKOV3 and OVCAR5 
cells were treated with everolimus at different concentrations as indicated (from 10 to 500 nM) for 24 h. Treatment with everolimus reduced 
the phosphorylated—S6 in a dose-dependent manner. Everolimus increased the expression of phosphorylated-AKT (Thr308 and Ser473) 
in the SKOV3 cell line, while decreased expression of phosphorylated-AKT (Ser473) was seen in the OVCAR5 cell line (A). *P < 0.05.
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to 72% in OVCAR5 cells, respectively, compared with 
euglycemic and hyperglycemic conditions (p < 0.05). 
Treatment with everolimus increased G1 phase arrest 
in ovarian cancer cells incubated under euglycemic and 
hypoglycemic conditions compared with hyperglycemia 
(p < 0.05) (Figure 5C). Similar shifts in annexin V 
expression induced by different concentrations of 
glucose were seen with SKOV3 and OVCAR5 cells 
(Figure 5D), suggesting that everolimus attenuated the 
cell cycle G1 phase and apoptosis under hyperglycemic 
conditions (p < 0.05). Western blotting results showed 
that hypoglycemia and euglycemic conditions induced a 
decrease in protein expression of cyclin D1 and MCL-1 
in both cells. The expression of cyclin D1 but not MCL-1 
was more profoundly influenced by everolimus under 
hypoglycemic conditions (Figure 5E). These results 
Figure 5: Glucose levels affected the sensitivity to everolimus in ovarian cancer cells. The SKOV3 and OVCAR5 cells were 
cultured in glucose-free media supplemented with 25 mM glucose (HG), 5 mM glucose (NG) and 1 mM glucose (LG) for 24 h and then 
treated with the indicated concentration of everolimus (from 10 nM to 500 nM) in 96-well plates for 48 h. Cell proliferation was assessed 
by MTT assay. LG increased the sensitivity to everolimus in inhibition of cell proliferation in both cells (A). The cells were treated with 
evorolimus (100 nM) for 24 h in the media supplemented with varying concentrations of glucose. Western blotting showed that HG 
obviously increased the expression of phosphorylated-S6 in the SKOV3 and OVCAR5 cells, while everolimus markedly decreased S6 
phosphorylation under euglycemic and hypoglycemic conditions (B). The analysis of the cell cycle showed that everolimus (100 nM) 
increased cell cycle phase G1 arrest under euglycemic and hypoglycemic conditions compared with the hyperglycemic condition after 24 h 
of treatment (C). Apoptosis was examined after SKOV3 and OVCAR5 were treated with everolimus (100 nM) at different concentrations 
of glucose for 24 h, and the results are displayed in graph (D). Cyclin D1 and Mcl-1 were determined by Western blotting in the SKOV3 and 
OVCAR5 cell lines after exposure to everolimus for 12 h with varying concentrations of glucose. HG induced an increase in expression of 
cyclin D1 and Mcl-1, and everolimus inhibited expression of cyclin D1 and Mcl-1 under euglycemic and hypoglycemic conditions (E). The 
cells were cultured for 24 h and then treated with the everolimus (100 nM) with varying concentrations of glucose for 24 h. The levels of 
cellular glucose uptake (F), cellular ATP and lactate productions (G and H) were detected. The results showed that hyperglycemia increased 
the rate of glucose uptake, the production of ATP and lactate levels. Everolimus significantly reduced the rate of glucose uptake, the level 
of ATP and lactate under all glucose culture conditions. *p < 0.05, **p < 0.01.
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suggest that everolimus exhibited greater induction of cell 
cycle G1 arrest and apoptosis under hypoglycemic and 
euglycemic versus hyperglycemic conditions in ovarian 
cancer cells.
Cancer cells exhibit enhanced glucose uptake, which 
in turn increases glycolysis and ATP production ultimately 
leading to enhanced tumor growth. We examined the effect 
of everolimus on glucose uptake and ATP levels in ovarian 
cancer cells incubated with different concentrations of 
glucose. Both cell lines were treated with everolimus 
at different concentrations of glucose for 24 hours. The 
rate of glucose uptake was increased with increasing 
glucose concentrations, whereas everolimus significantly 
reduced glucose uptake in each of the treatment groups 
(p < 0.05) (Figure 5F). Similarly, euglycemic and 
hyperglycemic versus hyperglycemic culture conditions 
caused a significant increase in the production of ATP and 
lactate (p < 0.05). Everolimus treatment also decreased 
the levels of ATP and lactate in each treatment groups 
(p < 0.05). However, the cells treated with everolimus 
under hyperglycemic conditions had less reduction in 
ATP (Figure 5G and 5H). Together, these results indicate 
that everolimus effectively inhibits glycolysis and might 
be more potent in hypoglycemic conditions than in 
hyperglycemic condition in ovarian cancer cells. 
Everolimus inhibits tumor growth in the KpB 
serous ovarian cancer mouse model
To further examine whether obesity could affect the 
anti-tumorigenic potential of everolimus in vivo, we used 
a transgenic serous ovarian cancer mouse model (KpB, 
K18-gT121
+/–; Brcar1f/f; p53f/f) fed a high fat diet (HFD) or 
low fat diet (LFD) at 3 weeks of age to induce obesity [9, 24]. 
The mice were divided into four groups: obese plus 
placebo, obese plus everolimus, lean plus placebo, and lean 
plus everolimus. The initial average body weight of the 
obese mice when starting treatment was 49.08 gm, while 
that of lean mice was 30.17 gm (p < 0.01, data not shown). 
EchoMRI showed body composition was significantly 
altered in obese KpB mice compared to lean controls. 
Obese mice had a two-fold greater percent body fat and a 
20% decrease in percent lean mass (p < 0.05) (Figure 6A). 
The levels of cholesterol were significantly increased 
in obese mice compared with lean mice (p < 0.05) 
(Figure 6B). However, there was no significant difference 
in random blood glucose between obese and lean mice 
over the course of the diet. When the tumor size reached 
0.1 × 0.1 cm in diameter by palpation, the mice in both 
groups were treated with either everolimus (3 mg/kg/day) 
or placebo (saline) for 4 weeks. During treatment, tumor 
growth was monitored by palpation twice a week. The 
mice showed tolerance to everolimus injections and 
maintained normal activities. Regular twice-weekly 
measurements yielded no changes in blood glucose, body 
composition or weight during everolimus or placebo 
treatment (data not shown). Mice were sacrificed at the 
end of treatment, and the ovarian tumors were removed, 
photographed and weighed. Obesity accelerated tumor 
growth with a 2.5 fold increase in tumor volume and a 
40% increase in tumor weight. Both obese and lean mice 
treated with everolimus had a significant reduction in 
tumor volume and weight (p < 0.05) (Figure 6C and 6D). 
Ovarian tumor weights were decreased by 66% in obese 
mice and by 60% in lean mice after treatment with 
everolimus for 4 weeks when compared with control mice 
(Figure 6C). These data suggest that obesity promotes 
ovarian tumor growth and everolimus effectively 
suppresses the ovarian tumor growth in both obese and 
lean KpB mice.
To further investigate the anti-tumorigenic activity 
and mechanism of everolimus in vivo, the expression 
of Ki-67, phosphorylated S6, phosphorylated AKT and 
cleaved caspase-3 in tumor tissues was evaluated by 
immunohistochemistry (Figure 6E). As expected, the 
expression of Ki-67 was significantly reduced following 
treatment by 64% and 25% compared to controls 
(p < 0.05), in the obese and lean groups, respectively. 
Everolimus treatment increased cleaved caspase-3 
expression from 17% in obese controls to 37% in obese 
treated mice as compared to 7% of lean controls and 21% 
in lean treated mice (p < 0.05). Consistent with our results 
in vitro, everolimus significantly reduced the expression 
of phosphorylated S6 and increased the expression of 
phosphorylated AKT (Ser473) in obese and lean mice 
compared with the untreated mice, suggesting that 
everolimus inhibited tumor growth through the mTORC1 
pathway in vivo (p < 0.05). Together, these results further 
confirm that everolimus inhibits tumor growth of ovarian 
cancer via targeting of the mTOR/S6 pathway and 
activation of apoptosis in vivo, regardless of obesity status. 
The effect of everolimus on metabolomic 
profiling in ovarian cancer of obese and lean 
mice 
We have previously observed significant ovarian 
tumor progression caused by obesity in the KpB mouse 
model accompanied by significant differences in 
metabolomic profiling between obese and lean mice [9] 
Given this, we sought to determine the effect of everolimus 
on metabolic pathways associated with cell proliferation 
in the KpB mouse model using metabolomics. 
Metabolites involved in polyamine metabolism were 
down-regulated after treatment with everolimus in both 
obese and lean KpB mice as compared to control mice, 
including putrescine, spermidine and N-acetylputrescine 
(p < 0.01). These results suggest that everolimus was 
able to reduce polyamines needed for packaging newly 
synthesized DNA into chromatin within the nucleus and 
are indicative of a decrease of cell proliferation in tumor 
tissues (Figure 7A). Increased phosphoenolpyruvate 
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(PEP) and decreased pyruvate levels in the glycolytic 
pathway were observed in obese and lean everolimus-
treated mice, suggesting everolimus inhibited glycolysis 
through inhibition of pyruvate kinase (PK), although 
glucose levels were 3 fold higher in the tumors of obese 
versus lean mice (p < 0.05) (Figure 7B). Lower levels of 
gut microbiome-associated metabolites and compounds 
absorbed from the diet: pipecolate, hippurate, catechol 
sulfate, stachydrine, ergothioneine and indolepropionate, 
were detected with everolimus treated obese and lean mice 
(p < 0.05), which could explain how mTOR suppression 
had systemic effects through alteration of the composition 
of circulating nutrients in tumor tissues (Figure 7C). 
The glycerophosphodiesters, glycerophosphocholine 
(GPC), glycerophosphoethanolamine (GPE) and 
glycerophosphoglycerol (GPG), were found to be 
significantly lower in obese and lean mice treated 
with everolimus (p < 0.05) (Figure 7D), reflecting that 
everolimus may activate glycerophosphodiesterase (s) in 
tumor tissues. Significant reductions of dipeptides were 
found in obese but not lean mice treated with everolimus, 
suggesting everolimus decreases protein degradation to 
a greater extent in obese mice (Figure 7E). Additionally, 
significant elevations of intermediates of pyrimidine 
metabolism were found in lean control mice (Figure 7F), 
which decreased significantly after everolimus treatment 
in lean but not obese mice. These metabolomic studies 
support that everolimus has differential actions depending 
on whether the ovarian tumors arise from obese or lean 
mice. 
Everolimus inhibited cell adhesion and invasion 
in ovarian cancer cells and KpB mice
Cell adhesion and invasion are the basic 
characteristics of tumor growth and metastasis in ovarian 
cancer. In order to determine the effect of everolimus on 
the adhesion and invasion potential of ovarian cancer cells, 
Figure 6: The effect of everolimus on the tumor growth in the KpB serous ovarian cancer mouse model. KpB mice 
were fed high fat diet (HFD) or low fat diet (LFD) at 3 weeks of age to induce obesity. The mice were divided into four groups: obese 
+ placebo, obese + everolimus, lean + placeobo and lean + everolimus. Echo MRI showed that HFD induced an increase in body 
fat composition in the KpB mice (A). The levels of cholesterol were significantly increased in obese mice compared with lean mice 
(B). The obese and lean mice in both groups were treated with everolimus (intraperitoneal injection, 3 mg/kg/day) or placebo. The graphs 
showed weekly tumor volumes for each group (C) and tumor weight after 4 weeks treatment (D). The changes of Ki-67, phosphorylated-S6, 
phosphorylated-AKT and cleaved caspase 3 were assessed by immunohistochemistry in the ovarian cancer tissues. The expression of Ki-67 
and phosphorylated-S6 was significantly reduced and cleaved caspase 3 and phosphorylated-AKT (Ser473) was increased in obese group 
after everolimus treatment compared with the lean group (E). *p < 0.05, **p < 0.01.
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both laminin adhesion and transwell invasion assays were 
performed. The SKVO3 and OVCAR5 cell lines were 
treated with everolimus at varying concentrations for 
24 hours for evaluation of cell adhesion and 2 hours 
for evaluation of invasion. There was significant 
inhibition of both cell adhesion and invasion in both 
cell lines (p < 0.05) (Figure 8A and 8B). Because the 
matrix metalloproteinase (MMP) family is involved in 
the breakdown of extracellular matrix in angiogenesis 
and metastatic processes, we next evaluated the 
MMP9 protein expression after 24 hours of everolimus 
treatment. Everolimus inhibited MMP9 expression in a 
dose-dependent manner in both cell lines (Figure 8C). 
Metabolomic profiling demonstrated that everolimus 
reduced degradation productions of collagen metabolites 
including pro-hydeoxy-pro and trans-4-hydroxyproline 
(p < 0.05) (Figure 8D), supporting the results of western 
blotting in the ovarian cancer cell lines. To further confirm 
the anti-metastatic activity of everolimus in vivo, IHC 
showed that the expression of VEGF was significantly 
reduced following everolimus treatment in obese and lean 
mice compared to the controls (p < 0.05) (Figure 8E). 
Similar results were found in (1) mouse serum of obese 
and lean mice and (2) the culture supernates of ovarian 
cancer cells treated with everolimus by ELISA assays 
(Figure 8F and 8G). 
DISCUSSION
The mTOR pathway is a central regulator of various 
oncogenic processes that contribute to cell proliferation, 
cell cycle progression, metabolism, angiogenesis and drug 
resistance in a wide variety of cancers including ovarian 
cancer [16]. In this study, we describe the anti-tumorigenic 
Figure 7: The effect of everolimus on small molecule composition involving metabolites in the KpB mouse model. 
Metabolomic profiling indicated that everolimus down-regulated arginine/putrescine/spermin metabolism in obese and lean KpB mice 
(A). Everolimus inhibited glycolytic activity in obese and lean KpB mice (B). The gut microbiome-associated metabolites and compounds were 
reduced in the lean and obese KpB mice after everolimus treatment (C). The glycerophosphocholine (GPC), glycerophosphoethanolamine 
(GPE), and glycerophosphoglycerol (GPG) were decreased in the obese and lean mice treated with everolimus (D). Dipeptide were 
significantly decreased in obese but not lean mice treated with evorolimus (E). The intermediates of pyrimidine metabolism were 
significantly decreased in the lean mice compared with obese mice after treatment with everolimus (F). 
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efficacy of everolimus attributed to inhibition of mTOR 
signaling in ovarian cancer, including obesity-driven 
tumors. Our results showed that treatment with everolimus 
resulted in a marked reduction in cell growth of ovarian 
cancer cells, both in established cell lines and primary 
cultures, which was accompanied by induction of cell 
cycle arrest, apoptosis and cellular stress. Hyperglycemic 
conditions increased cell proliferation, and hypoglycemic 
conditions enhanced the sensitivity to everolimus through 
disruption of glycolysis. Moreover, everolimus reduced 
ovarian tumor weight and volume in both obese and lean 
KpB mice. This reduction in tumor weight and volume 
coincided with a decrease in expression of Ki-67 and 
phosphorylated-S6, as well as an increase in cleaved 
caspase 3 and phosphorylated-AKT, suggesting that 
everolimus increased AKT activity in in vivo models 
[25]. In addition, inhibition of adhesion and invasion 
was observed after treatment with everolimus in vitro 
and reduction of VEGF production in vivo. Inhibition of 
mTOR activity by everolimus was effective in altering 
tumor metabolism with a profound effect on glycolysis, 
polyamines, dipeptides, glycerophosphodiesters, and 
nucleotides in both obese and lean KpB mice. These 
results support that everolimus is a promising anti-
tumorigenic agent for the treatment of ovarian cancer, 
including obesity-driven cancer. 
Everolimus has been shown to exhibit potent pre-
clinical activities against a wide variety of cancers via 
induction of cell cycle arrest in G1 phase and apoptosis, 
including ovarian cancer, small cell lung cancer, renal cell 
carcinoma, pancreatic cancer and leukemias [17, 26–28]. 
Through inhibition of mTORC1 function, everolimus 
blocks essential translational events, including decreases 
in translation of cyclin D1, c-Myc, hypoxia-inducible 
transcription factor 1a, ornithine decarboxylase, VEGF 
and fibroblast growth factor. Ultimately, this results in 
a decrease of cell proliferation, inhibition of cell cycle 
progression, alterations in metabolism and induction of 
apoptosis [17]. Treatment with everolimus has been found 
to inhibit intra-abdominal dissemination and production 
of ascites and prolong survival in a xenograft model of 
ovarian cancer [27]. Everolimus has been also shown to 
Figure 8: The effect of everolimus on adhesion and invasion in ovarian cancer cells and the obese serous ovarian 
cancer model. The SKOV3 and OVCAR5 cells were cultured for 24 h and then treated with everolimus (100 nM) in a laminin coated 
96 well plate or BME coated 96 transwell plate for 24 h or 2 h to asses adhesion and invasion in a plate reader, respectively (A and B). 
Everolimus reduced cell adhesion and invasion in both cell lines. The MMP-9 protein was downregulated in the SKOV3 and OVCAR5 
cell lines after treatment with everolimus for 24 h (C). In the KpB mouse model, metabolomic profiling showed that everolimus induced 
a degradation of collagen metabolites in obese and lean mice (D). Immunohistochemical analysis showed that the expression of VEGF 
protein was significantly decreased after everolimus treatment in lean and obese mouse (E). The level of VEGF after treatment in lean and 
obese mouse serum was measured by ELISA assays (F). SKOV3 and OVCAR5 cells were treated with everolimus at 10 to 500 nM for 
24 h. The supernates from culture media were measured by ELISA assay. The results showed that everolimus decreased VEGF production 
in ovarian cancer cell lines (H). *p < 0.05, **p < 0.01.
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delay tumor onset and progression in a TgMISIIR-TAg 
transgenic mouse model of ovarian cancer [26]. Our data 
finds that everolimus inhibited cell proliferation in five 
ovarian cancer cell lines, as well as ten primary cell cultures 
of ovarian cancer through induction of cell cycle G1 arrest 
and apoptosis. Although IC50 values (more than 10 uM) 
could not be attained with the primary cultures, MTT assays 
produced nearly flat curves across various concentrations of 
everolimus from 1 nM to 5 uM in five ovarian cancer cell 
lines, indicating that low doses of everolimus were effective 
in inhibition of cell proliferation in ovarian cancer. The 
concentration of everolimus (1–10 nM) is very close to the 
therapeutic range recommended (3–8 nM) for everolimus 
as an immunosuppressant drug at an oral daily dose of 
1.5 mg/day. Mabuchi et. al. report that response to 
everolimus in mouse models does not correlate with 
the sensitivity to everolimus in vitro in ovarian cancer 
[26]. Another study also suggests that in vivo efficacy 
of everolimus depended on considerably lower plasma 
concentrations of everolimus in leukemia [29]. Consistent 
with this data, our in vivo results show that everolimus 
effectively inhibits tumor growth in a transgenic mouse 
model of ovarian cancer fed with either HFD or LFD. The 
precise mechanism to explain this difference in in vitro and 
in vivo sensitivity to everolimus remains unknown. It has 
been proposed that everolimus acts as an allosteric inhibitor 
in vitro resulting in a flat dose–response curve [30] 
Obesity is a known risk factor for ovarian cancer, 
but it is not clear how obesity contributes to carcinogenesis 
and progression of ovarian cancer. Long term feeding 
with a HFD in mice initially induces a positive fat balance 
between fat oxidation and consumption and eventually 
results in weight gain and fat accumulation [31, 32]. 
HFD exposure leads to increased levels of cholesterol, 
triglycerides, adiponectin, proinflammatory cytokines, 
insulin as well as leptin resistance. These obesity-
driven effects subsequently promote the development 
of cancer, including breast, prostate, liver, and ovarian 
cancer [33–35]. A recent study showed that exposure to 
a HFD efficiently activates oncogenic K-ras activity and 
up-regulates COX2 expression to induce development 
of pancreatic ductal adenocarcinoma in transgenic mice 
[36]. High expression of adiponectin in ovarian cancer 
tissues has an ability to mediate cell proliferation and 
metabolism [37]. Inflammatory cytokines, such as 
tumor necrosis factor (TNF)-α, interleukin (IL)-1β and 
IL-6, produced by a tumor and/or activated by immune 
cells, have been shown to stimulate cancer cell growth 
and influence clinical disease status and prognosis [38]. 
Increased glycolytic metabolism has been observed in 
ovarian cancer cells, and adipocytes have been found 
to promote ovarian cancer cell proliferation, migration, 
expression of cancer associated genes and bio-energetic 
changes [39, 40]. Additionally, HFD exposure markedly 
stimulates ovarian tumor growth by up to 6-fold in nude 
mice compared with controls [41]. The above data all 
suggests that obesity is associated with the development 
and progression of ovarian cancer through multiple steps 
and signaling pathways. 
Given that obesity-induced tumor growth involves 
alterations in AKT/mTOR signaling, everolimus may be 
a logical choice in obese ovarian cancer patients [42]. In 
the present study, we induced obesity in the KpB mouse 
model using a HFD. Mice fed a HFD developed obesity as 
indicated by increased body weight and fat accumulation, 
as well as metabolic consequences associated with 
obesity [32]. The obese mice exhibited much greater 
tumor volume and tumor size than lean mice. Although 
everolimus inhibited tumor growth in both obese and 
lean mice, our in vitro results showed that hypoglycemic 
conditions significantly increased the sensitivity to 
everolimus. Everolimus showed increased inhibition of 
cell proliferation through targeting apoptosis, cell cycle 
arrest and activation of the mTOR/S6 pathway. Given that 
our mouse model had no difference between serum blood 
glucose concentrations in obese and lean mice, the effects 
of the glycemic environment could not be replicated 
in vivo. Because it was observed that phosphorylation 
of AKT and S6 can be elevated by the hyperglycemic 
condition in ovarian cancer cells, it is possible that AKT 
and S6 activities and negative feedback mechanisms are 
involved in inhibition of cell growth by everolimus at 
varying glucose concentrations in ovarian cancer cells 
[16, 25, 43]. 
Metabolomics offers unbiased identification 
of subtle changes in small molecule composition 
(metabolites < 2,000 Da) involving metabolites as affected 
by signaling pathways and genetic factors, and opens new 
avenues to investigate the dysregulation of metabolism in 
cancer biology, cancer diagnosis and chemotherapeutic 
strategies [44, 45]. Through this approach, we have 
previously shown that metabolomic profiling exhibited 
significant differences between ovarian tumors from 
obese versus lean mice, including metabolically relevant 
pathways [9]. Similarly, the present metabolic profiling 
analysis found that ovarian tumors in obese mice have 
a distinct metabolic signature compared to tumors in 
lean mice. Everolimus reduced polyamine metabolism 
required for cell proliferation in obese and lean mice. 
Recent studies demonstrated that targeting polyamine 
metabolism has been shown to inhibit the tumor growth 
in vitro and in vivo, and cisplatin resistance in ovarian 
cancer cell lines is associated with polyamine synthesis 
[46–48]. A major metabolic hallmark of cancer is the 
frequently elevated glycolytic activity through a shift 
from oxidative phosphorylation to glycolysis, despite 
the presence of oxygen, known as the Warburg effect. 
Inhibition of the mTOR pathway reduces glucose uptake 
by reducing glucose transporter 1 (GLUT1) expression 
and/or hexokinase activity [49]. Consistent with previous 
studies, we found that everolimus significantly inhibited 
glucose uptake and reduced the production of lactate in 
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ovarian cancer cells. We also found increased PEP and 
decreased pyruvate in tumor tissues in obese and lean 
mice, indicating that everolimus inhibited glycolysis 
through different targets, particularly with pyruvate 
kinase in the mice [50]. Recent data suggests that the gut 
microbiota affect nutrient acquisition, energy harvest and 
the development of obesity and diabetes [51]. Our results 
found that everolimus, via mTOR suppression, effectively 
reduced gut microbiome-associated metabolites in both 
obese and lean tumor tissues. These results suggest that 
everolimus can decrease gut microbiome-associated 
metabolites and compounds absorbed from the diet, which 
may blunt the penetration of these metabolites into ovarian 
cancer tissues. This could result in a reduced nutrient 
supply to ovarian cancer for growth. The implications and 
mechanisms underlying everolimus’s metabolic effects on 
tumor growth are definitely worthy of further exploration. 
Three metabolites (glycerophosphodiesters family) 
associated with lipid metabolism, glycerophosphocholine 
(GPC), glycerophospho ethanolamine (GPE), and 
glycerophosphoglycerol (GPG) were significantly 
reduced with everolimus treatment in obese and lean 
mice. Glycerophosphodiesters are conserved proteins 
that contribute to cell proliferation, differentiation 
and invasion in cancer [52]. GPC is a precursor of 
phosphatidylcholine (PC), while cleavage of GPC by EDI3 
(glycerophosphodiesterase), results in the formation of 
both choline and glycerol-3-phosphate (G3P) [53], which 
are closely associated with cell proliferation in cancer [54]. 
Patients with moderately to poorly differentiated ovarian 
cancer have higher concentrations of choline in their 
tumors [55]. Elevated Ki-67, GPC and PC were found in 
the patients with high-grade prostate cancer [56]. Ovarian 
cancer tissues showed a significantly decreased GPC and 
GPE production following ex vivo exposure to paclitaxel, 
cisplatin and carboplatin [55]. Hutschenreuther et. al. 
reported that a higher concentration of GPG is responsible 
for aerobic glycolysis and enhanced aggressiveness in 
breast cancer. It is hypothesized that increased GPG 
provides ATP production, maintains integrity of cellular 
membranes and participates in signaling including 
cell migration [57]. These results could indicate that 
the mTOR pathway plays a role in the regulation of 
glycerophosphodiesters metabolism. GPC, GPE and GPG 
may be involved in inhibition of tumor growth induced 
by everolimus in ovarian cancer. It is not clear whether 
reduced levels of GPC, GPE, and GPG are the result of 
less phospholipid breakdown or more.
In addition to its effects on cell growth, everolimus 
decreased cell adhesion and invasion in ovarian cell lines 
and VEGF expression in the KpB mice. Metabolomic 
profiling showed everolimus significantly decreased the 
degradation products of collagen metabolites in tumor 
tissues and MMP9 expression in ovarian cancer cells, 
respectively. This suggests that everolimus has the ability 
to inhibit the invasive properties of ovarian cancer through 
suppression of matrix metalloproteinase. Although 
it remains to be determined if everolimus has other 
underlying mechanisms to inhibit adhesion and invasion, 
these results clearly indicate an additional benefit of 
everolimus for the treatment of ovarian cancer alongside 
reduction in cell growth. Indeed, the ability to prevent cell 
invasion could have important clinical implications, given 
the unique challenges in treating this cancer particularly 
involving invasion, metastasis, recurrence and drug 
resistance [2]. Multiple studies have confirmed that 
everolimus has the potential to inhibit angiogenesis and 
invasive ability in prostate cancer, esophageal cancer, head 
and neck cancers, glioma, multiple myeloma, and ovarian 
cancer [49, 58–62]. 
The main side effects reported in clinical trials 
include stomatitis, rash, fatigue, and diarrhea, pulmonary 
dysfunction, hypercholesterolemia, hypertriglyceridemia, 
mild leukocytopenia and thrombocytopenia [21, 23, 63]. 
Hyperglycemia and hypercholesterolemia are other 
potential metabolic adverse events seen with everolimus 
treatment. These metabolic changes are associated with 
the effects of everolimus on mTOR pathway inhibition 
[64]. These effects are generally mild to moderated 
in severity, have a low incidence and are clinically 
manageable [65]. There are several possible mechanisms 
by which everolimus may cause hyperglycemia and 
hypercholesterolemia, including impaired insulin-
mediated suppression of hepatic glucose production, 
insulin resistance and reduction of glucose uptake 
for hyperglycemia and reduction of lipid uptake for 
hypercholesterolemia [66]. In our study, everolimus 
treatment did not change the blood glucose or cholesterol 
levels in either obese or lean mice, suggesting a possible 
difference between metabolism in humans or mice. Given 
that the mTOR pathway is highly activated with increased 
severity of obesity in humans, everolimus may be more 
successful when used in obese patients with ovarian 
cancer by reducing mTOR activity. While our in vivo 
results showed that everolimus has equivalent function in 
obese and lean mice, the significant increase in tumor size 
seen in the obese mice may account for our inability to 
detect improved function in obese mice. Regardless, given 
that everolimus effectively inhibited growth of ovarian 
cancer in obese mice, everolimus may be a good candidate 
for ovarian cancer patients with obesity. However, 
considering everolimus’s metabolic adverse events, it may 
be necessary to optimize levels of lipid and blood glucose 
before initiating treatment, monitor the changes of blood 
glucose and cholesterol periodically during the treatment 
and treat hyperglycemia and hypercholesterolemia 
according to standard consensus guidelines [23, 63, 66].
Currently, mTOR inhibitors are being studied 
clinically for use in the treatment of cancers as a single 
agent or in combination with other chemotherapeutic 
agents. Several phase I–II clinical trials are now ongoing 
with mTOR inhibitors in patients with ovarian cancer. A 
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recent critical review indicated that inhibiting a single 
pathway using mTOR inhibitors may not be sufficient 
to stop tumor growth; and thus, clinical response may be 
improved by designing combination therapy protocols. 
Indeed, tumors respond to mTOR inhibition by creating 
a negative feedback loop with increased activation of the 
AKT activity or crosstalk to other signaling pathways 
to maintain their function, which results in escape from 
drug-induced growth inhibition [16]. Alternatively, 
screening for PIK3CA mutations with targeted use of 
mTOR inhibitors may be another useful strategy since 
patients with these mutations may be more responsive 
to PI3K/AKT/mTOR inhibitors than patients without 
these mutations in gynecologic cancers [3]. Thus, the 
relationship between clinical response to everolimus and 
PIK3CA mutations, as well as the role of combination 
therapy, warrants further investigation in clinical trials in 
ovarian cancer, including those in obese and lean women. 
MATERIALS AND METHODS
Cell culture and reagents
The human ovarian cancer cell lines, HEY, SKOV3, 
OVCAR5, IGROV1 and OV433 were used. The SKOV3 and 
OVCAR5 cell lines were maintained in DMEM/F12 medium 
with 5% fetal bovine serum (FBS). The IGROV1 and OV433 
cell lines were maintained in RPMI 1640 with 10% FBS. The 
HEY cell line was maintained in RPMI 1640 with 5% FBS. 
All medium was supplemented with 100 U/ml of penicillin 
and 100 ug/ml of streptomycin. The cells were cultured in a 
humidified 5% CO2 at 37°C. For glucose studies, the SKOV3 
and OVCAR5 cell lines were cultured in DMEM medium 
without glucose (Cat # 11966–025, Gibco), containing 10% 
dialyzed FBS and supplied with specific concentrations of 
glucose (1 mM, 5 mM and 25 mM).
Glucose solution, MTT and DMSO were purchased 
from Sigma-Aldrich (St. Louis, MO). 2-NBDG 
(2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-
Deoxyglucose) was bought from Life Technologies 
(Grand Island, NY). Enhanced chemiluminescence (ECL) 
detection reagents were purchased from GE Health care 
(Piscataway, NJ). The non-fat milk, 20% bull serum 
albumin (BSA) and RNase A were purchased from Sigma 
(St. Louis, MO, USA ), and all the primary antibodies 
for phosphorylated-S6, pan-S6, phosphorylated-AKT, 
pan-AKT, cyclin D1, CDK6, p21 ,Bcl-2, Mcl-1, Ki-67, 
VEGF, cleaved caspase 3, perk, bip, calnexin, MMP-9 and 
α-tubulin were obtained from Cell Signaling Technology 
(Danvers, MA, USA). 
Cell proliferation assay
The SKOV3 and OVCAR5 cell lines were seeded 
at 4000 cells/well in 96-well plates in regular media 
for 24 h. Cells were subsequently treated with varying 
concentration of everolimus (from 0.01 to 25000 nM) 
for 72 h. MTT (5 mg/ml) was added to the 96-well plates 
at 5 μl/well for 1 h. The MTT reaction was terminated 
through the addition of 100 μl of DMSO. Viable cell 
densities were determined by measuring absorbance of 
metabolic conversion of the colorimetric dye at 570 nm. 
For the glucose experiments, SKOV3 and OVCAR5 cells 
were seeded at 4000 cells/well in 96-well plates in regular 
media for 24 h and then treated with different doses of 
everolimus (from 10 to 500 nm) for 48 h in media supplied 
with 1, 5 and 25 mM glucose. Cell proliferation was 
measured by MTT assay. Each experiment was performed 
in triplicate to assess for consistency of results.
Colony formation assay
The SKOV3 and OVCAR5 cells growing in log 
phase were seeded (800 cells/well in a 6-well plate) in 
their normal growth media. Cells were allowed to adhere 
for 24 hours, and then treated with everolimus (0, 1 and 
100 nM) for 24 hours. Cells were cultured at 37°C for 
14 days, with media changes every third or fourth day. 
Cells were stained with 0.5% crystal violet, and colonies 
were counted under the microscope. Colony formation 
assays were performed in duplicate.
Cell cycle analysis
The SKOV3 and OVCAR5 cells were seeded at 
2.5 × 105 cells/well into 6-well plates and incubated 
overnight, and then treated with everolimus (10, 100 and 
500 nM) in regular medium for 48 hours. The cells were 
harvested and washed with phosphate buffered saline (PBS). 
The pellet was re-suspended and fixed in 90% pre-chilled 
methanol and stored overnight at −20°C. The cells were then 
washed with PBS again and re-suspended in 50 μl RNase A 
solution (250 μg/ml, 10 mM EDTA) for 30 minutes and then 
stained with 50 μl of staining solution [containing 2 mg/ml 
Propidium iodide (Hayward, MA, USA), 0.1 mg/ml Azide 
(Sigma) and 0.05% Triton X-100 (Sigma)]. The final mixture 
was incubated for 15 minutes in the dark before analyzing 
with Cellometer (Nexelom, Lawrence, MA). The results 
were evaluated using FCS4 express software (Molecular 
Devices, Sunnyvale, CA). For the glucose experiments, 
the SKOV3 and OV5 cells were seeded at 2.5 × 105 
cells/well into 6-well plates and incubated overnight in 
regular media, and then treated with 100 nM everolimus for 
48 h in media with different concentrations of glucose. Cell 
cycle was measured by Cellometer. All experiments were 
performed in triplicate and repeated three times.
Apoptosis assay
Apoptosis was detected with the Annexin V FITC 
kit (Biolegend, San Diego, CA) with Cellometer. Briefly, 
2 × 105 cells/well were seeded into 6-well plates, incubated 
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overnight and then treated with everolimus (from 0 to 
500 nM) in regular medium for 24 h. The cells were then 
collected, washed with PBS and re-suspended in 100 μl 
binding buffer. Subsequently, 1 μl of annexin V-FITC 
(100 ug/ml) and 0.5 uL of propidium iodide (2 mg/ml) 
were added in the binding buffer and placed in the dark 
for 15 minutes. The samples were immediately measured 
by Cellometer. The results were analyzed by FCS4. For 
the glucose experiments, the SKOV3 and OV5 cells were 
seeded at 2.5 × 105 cells/well into 6-well plates and incubated 
overnight in regular media, and then treated with 100 nM 
everolimus for 24 h in media with different concentrations 
of glucose. Apoptosis was evaluated using Annexin V FITC 
kit on the Cellometer. All experiments were performed in 
triplicate to assess for consistency of response.
Adhesion assay
Each well in a 96-well plate was coated with 100 μl 
laminin-1 (10 ug/ml) and incubated at 37°C for 1 h. The 
fluid was then aspirated and 200 μl blocking buffer was 
added to each well for 45–60 min at 37°C. The wells were 
washed with PBS, and the plate was allowed to chill on 
ice. To each well, 2.5 × 103 cells were added with PBS and 
varying concentrations of everolimus directly. The plate 
was then allowed to incubate at 37°C for 2 h. The medium 
was then aspirated, and the cells were fixed by directly 
adding 100 μl of 5% glutaraldehyde and incubating for 
30 min at room temperature. Adhered cells were then 
washed with PBS and stained with 100 μl of 0.1% crystal 
violet for 30 minutes. The cells were washed repeatedly 
with water, and then 100 μl of 10% acetic acid was added 
to each well to solubilize the dye. After 5 minutes of 
shaking, the absorbance was measured at 570 nm, using 
a microplate reader from Tecan (Morrisville, NC). All 
experiments were performed in duplicate to assess for 
consistency of response.
Invasion assay
Cell invasion assays were performed using 96-well 
HTS transwells (Corning Life Sciences, Wilmington, 
NC) coated with 0.5–1X BME (Trevigen, Gaithersburg, 
Maryland). Starved (serum-free media for 12 h) SKOV3 
and OVCAR5 cells (50,000 cells/well) were seeded for 
12 h in the upper chambers of the wells in 50 μl FBS-free 
medium, and the lower chambers were filled with 150 μl 
regular medium with different concentrations of everolimus. 
The plate was incubated for 24 h at 37°C to allow invasion 
into the lower chamber. After washing the upper and lower 
chambers with PBS once, 100 μl Calcein AM solution was 
added into the lower chamber and incubated at 37°C for 
30–60 minutes. The lower chamber plate was measured 
by the plate reader for reading fluorescence at EX/EM 
485/520 nM. All experiments were performed in duplicate 
to assess for consistency of response.
Reactive oxygen species (ROS) assay
ROS generation was assessed using the ROS-
sensitive fluorescence indicator, DCFH-DA. To determine 
intracellular ROS scavenging activity, the SKOV3 and 
OVCAR5 cells (1.0 × 104 cells/well) were seeded in black 
96-well plates. After 24 h, the cells were treated with 10, 
100 and 500 nM of everolimus for 12 h to induce ROS 
generation. After the cells were incubated with DCFH-
DA (20 μM) for 30 minutes, the fluorescence intensity 
was measured at an excitation wavelength of 485 nm and 
an emission wavelength of 530 nm using a plate reader 
(Tecan). All experiments were performed in duplicate to 
assess for consistency of response.
Glucose uptake assay
The SKOV3 and OVCAR5 cells were seeded into 
96-well plates at 4000 cells per well overnight and then 
were treated with 100 nM everolimus under varying 
concentrations of glucose for 24 hours. After treatment, 
the SKOV3 and OV5 cells incubated with 2-NBDG 
(100 μM) with glucose free medium for 15 minutes. 
The medium was then replaced with 200 μl HBSS (Life 
technologies corporation, Grand Island, NY), and the plate 
was centrifuged for 5 min at 400 rpm. The fluorescence 
intensity was measured at an excitation wavelength of 
485 nm and an emission wavelength of 530 nm using 
a plate reader from Tecan. Glucose uptake assays were 
performed in duplicate.
Measurement of ATP
ATP production was determined using the 
luminometric ATP assay kit (AAT bioquest, Sunnyvale, 
CA, USA), following the manufacturer’s instructions. 
In brief, 5 × 103 cells were seeded in 96-well plates 
and incubated overnight, followed by treatment with 
everolimus (100 nM) under varying concentrations of 
glucose for 24 hours. 100 μl/well ATP assay solution was 
then added, mixed gently and incubated for 20 minutes 
at room temperature. The luminescence intensity was 
measured in luminometer mode on a Tecan plate reader. 
Finally, the ATP levels were normalized based on the 
viable cell counts measured by the MTT assays. The 
experiments were performed in triplicate and repeated 
three times.
Lactate production assay
Lactate production in the medium was detected 
using the Lactate Assay Kit (BioVision, Mountain View, 
CA, USA). Briefly, cells were treated with everolimus 
(100 nM) for 24 h under varying concentrations of 
glucose. 2 μl of corresponding media was then removed 
for the lactate assay. The media was mixed with reaction 
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buffer and incubated for 30 minutes at 37°C in the dark. 
Fluorescence was then measured at Ex/Em = 535/587 nm 
on a microplate reader. Results were normalized on the 
basis of the total protein concentration of each sample. 
All the experiments were performed in triplicate and 
repeated twice.
Western blot analysis
Total protein was extracted from the SKOV3 and 
OVCAR5 cells using RIPA buffer (Boston Bioproducts, 
Ashland, MA). Protein samples with equal loading (30 ug) 
were separated by 10–12% SDS-PAGE and transferred 
onto polyvinylidene fluoride (PVDF) membranes. The 
membranes were blocked with 5% nonfat milk and then 
incubated with a 1: 1000 dilution of primary antibodies 
for overnight at 4°C. The membranes were washed 
and incubated with a secondary peroxidase-conjugeted 
antibody for 1 hour at room temperature. The membranes 
were developed using an enhanced ECL at Alpha Innotech 
Imaging System (Protein Simple, Santa Clara, CA). 
After developing, the membranes were re-probed using 
antibody against α-tubulin to confirm equal loading. 
The bands’ intensity were measured and normalized to 
α-tubulin. Each experiment was repeated at least twice 
for consistency of results.
VEGF assay
To measure VEGF levels, the SKOV3 and 
OVCAR5 cell lines (2.5 × 105 cells) were plated in 6-well 
plates and incubated under standard culture conditions 
overnight. Subsequently, the medium was replaced by 
serum-free culture medium, and varying concentrations 
of everolimus were added. The medium was collected 
after 48 h of exposure to everolimus. 10–50 μl of culture 
medium was used to measure the levels of VEGF with a 
VEGF ELISA kit (DVE00, R & D Systems, Minneapolis, 
MN), according to the manufacturer’s instructions. The 
optical density at 570 nm of each well was measured using 
a Tecan reader. The VEGF concentration in the serum of 
mice after exposure to everolimus was measured by the 
same VEGF ELISA kit.
Obesity and the K18−gT121
+/– ;p53fl/fl;Brca1fl/fl 
mouse model
The K18−gT121
+/– ;p53fl/fl;Brca1fl/fl (KpB) mouse 
model is a unique serous ovarian cancer mouse model, 
wherein the tumor suppressor genes, Brca1 and p53 are 
specifically and somatically deleted and the retinoblastoma 
(Rb) proteins are inactivated in the adult ovarian surface 
epithelium. Inactivation of all 3 Rb proteins by T121 
(a fragment of the SV40 large T antigen) is driven by the 
keratin 18 (K18) promoter. Expression of the T121 transgene 
and knockout of p53 and Brca1 are conditional and only 
activated via injection of an adenoviral vector expressing 
Cre (AdCre) into the ovarian bursa cavity of adult female 
mice. At approximately 6 months after AdCre injection, 
tumors develop in the affected ovary, while the un-injected 
ovary remains normal [24].
For the evaluation of everolimus in the KpB mouse 
model, 30 mice were provided a high-fat diet (HFD, 
obese group) (60% kcal from fat, Research Diets, New 
Brunswick, NJ) to induce obesity and 30 mice were 
provided a low-fat, control diet (LFD, lean group) (10% 
kcal from fat, Research Diets, New Brunswick, NJ) 
ad libitum, beginning at 3 weeks of age. Recombinant 
adenovirus Ad5-CMV-Cre (AdCre) was purchased from 
the University of Iowa Transfer Vector Core at a titer of 
1011–1012 infectious particles/ml. AdCre injection occurred 
at 6–8 weeks to induce ovarian cancer 6 months later 
(at 8 months of age) [21]. Thirty-six hours following 
superovulation, the mice were anesthetized, and a 
single 1 cm incision was made on the dorsal surface of 
each mouse. The AdCre was then injected via a needle 
introduced into the oviduct near the infundibulum and 
into the ovarian bursa, and the incision was closed. All 
experimental animals were maintained in accordance 
with the Institutional Animal Care and Use Committee 
(IACUC) and the NIH guide for the Care and Use of 
Laboratory Animals. After AdCre injection, each group 
was randomly divided into control, placebo (saline) 
group and everolimus treatment group (obese + placebo, 
obese + everolimus, lean + placebo, lean + everolimus). 
When tumor size reached 0.1 × 0.1 cm in diameter by 
palpation, the mice in both groups were treated with 
everolimus (intraperitoneal injection, 3 mg/kg/day) 
or placebo. Tumors were palpated and measured by 
calipers twice a week. After four weeks of everolimus 
or placebo treatment, mice were euthanized and tumor 
tissue and blood samples were collected. Tumor volume 
was calculated using the following equation: tumor 
volume = (width2 × length)/2. 
Immunohistochemical analysis
The mouse tumor tissue was formalin-fixed and 
paraffin-embedded. Slides (5 μm) were first incubated with 
Protein Block solution (Dako) for 1 hour and then with the 
primary antibodies for Ki-67 (1:400), phosphorylated-S6 
(1:300), VEGF (1:500), phosphorylated-AKT (1:400) and 
cleaved caspase 3 (1: 300) for 2 hours at room temperature. 
The slides were then washed and incubated with 
appropriate secondary antibodies at room temperature for 
1 hour. The slides were washed, and the specific staining 
was visualized using the Signal Stain Boost IHC Detection 
Reagent (Cell Signaling Technology), following the 
manufacturer’s instructions. Individual slides were scanned 
using the Aperio™ ScanScope (Aperio Technologies, Vista, 
CA) and digital images were analyzed for target protein 
expression using Aperio™ ImageScope software.
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Body weight and composition
Prior to starting mice on diet and until sacrifice, 
body weight was measured weekly. Body composition, 
including lean mass, fat mass, free water content and total 
water content, of the obese and lean groups was measured 
at pre- and post-diet exposures using the EchoMRI-100 
quantitative magnetic resonance whole body composition 
analyzer (Echo Medical Systems, Houston, TX).
Blood cholesterol
Blood cholesterol from the mice was measured by 
an automated blood chemical analyzer (Ortho Clinical 
Diagnostic Inc, Rochester, NY) in the UNC-CH Animal 
Facility Laboratory, Department of Pathology, UNC, 
Chapel Hill. 
Metabolomic profiling
Metabolomic profiling was performed on ovarian 
tumors from control and metformin treated lean and 
obese mice. Samples were analyzed by Metabolon 
(Research Triangle Park, NC) according to their 
standard protocols [67–70]. Briefly, unbiased global 
metabolomic profiling was achieved using methanol 
extracts of tumor tissues normalized to serum volume 
or tissue weight. Analysis of extracts consisted of either 
ultrahigh performance liquid chromatography (Waters 
Corporation, Milford, MA) coupled with tandem mass 
spectrometry (UHPLC/MS/MS; Thermo-Finnigan, San 
Jose CA) in positive and negative ionization modes, or 
via gas chromatography/MS analysis (Thermo-Finnigan). 
Metabolites in tumor tissues were positively identified 
by matching chromatographic retention time, mass and 
MS/MS fragmentation patterns to a reference library of 
over 2500 purified, authenticated biochemicals. Data are 
presented as relative measures of “scaled intensity” and 
median scaling to 1. Missing values were imputed with 
the minimum.
Gas chromatography time-of-flight mass 
spectrometry (GC-TOFMS, Leco Corporation, St 
Joseph, MI) and liquid chromatography coupled with 
time-of-flight mass spectrometry(LC-TOFMS, Agilent 
Corporation, Santa Clara, CA) were used to analyze 
tumors from the four groups (N = 5/group) at Metabolon 
Inc (Durham, NC, USA) following our previous 
publication [9]. Metabolite annotation was performed by 
comparing the mass spectrum and retention time to an in-
house library and NIST library (GC-TOMFS) or HMDB 
(LC-TOFMS). Compounds were identified by comparison 
to library entries of purified standards or recurrent 
unknown entities. Identification of known chemical 
entities was based on comparison to metabolomic library 
entries of purified standards based on chromatographic 
properties and mass spectra. 
Ovarian cancer tissue samples collection and 
primary cell culture
Ten tumor specimens were sampled from patients 
undergoing surgery for primary serous ovarian carcinoma 
at the University of North Carolina at Chapel Hill 
(UNC-CH). The protocol was reviewed and approved 
by the Institutional Review Board at UNC-CH. Tumors 
were staged and graded according to the criteria of the 
International Federation of Obstetrics and Gynecology 
(FIGO, 2009). For the primary cultures of human 
ovarian cancer cells, the freshly obtained tissues were 
washed three times with Hank’s Buffered Salt Solution 
(HBSS), and then gently minced by scissors in DMEM/
F12 medium containing 10% fetal bovine serum (FBS). 
These tissues were then digested in 0.2% collagenase IA, 
100 U/ml penicillin and streptomycin for 30–60 minutes 
at 37°C water bath with shaking. After two centrifugations 
with PBS solution, cells were re-suspended and diluted to 
1 × 105 cells/ml with DMEM/F12 medium. Subsequently, 
1 × 104 cells/well were seeded into 96-well plates for 24 h, 
and then treated with everolimus as indicated for 72 h. 
Cell proliferation was measured by MTT assay. 
Statistical analysis
Results were compared by Student’s t test and data 
were expressed as mean ± S.E. Statistical significance was 
defined to be p < 0.05. 
ACKNOWLEDGMENTS AND FUNDING
This work is supported by a Department of Defense/
Ovarian Cancer Research Program (DOD/OCRP), the 
Steelman Fund, Translational Pilot Award (OC110163) 
and National Natural Science Foundation of China 
(81372778).
CONFLICTS OF INTEREST
The authors declare that they have no competing 
interests.
REFERENCES
 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. 
CA Cancer J Clin. 2015; 65:5–29.
 2. Mirandola L, M JC, Cobos E, Bernardini G, Jenkins MR, 
Kast WM, Chiriva-Internati M. Cancer testis antigens: novel 
biomarkers and targeTable proteins for ovarian cancer. 
International reviews of immunology. 2011; 30:127–137.
 3. Husseinzadeh N, Husseinzadeh HD. mTOR inhibitors 
and their clinical application in cervical, endometrial and 
ovarian cancers: a critical review. Gynecologic oncology. 
2014; 133:375–381.
Oncotarget20354www.impactjournals.com/oncotarget
 4. Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, 
deFazio A, Fereday S, Hung J, Johnatty SE, Australian 
Ovarian Cancer Study G, Fasching PA, Beckmann MW, 
Lambrechts D, et al. Obesity and survival among women 
with ovarian cancer: results from the Ovarian Cancer 
Association Consortium. British journal of cancer. 2015.
 5. Protani MM, Nagle CM, Webb PM. Obesity and ovarian 
cancer survival: a systematic review and meta-analysis. 
Cancer prevention research. 2012; 5:901–910.
 6. Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, 
Lagasse LD, Li AJ. Effect of obesity on survival in 
epithelial ovarian cancer. Cancer. 2006; 107:1520–1524.
 7. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity 
and cancer—mechanisms underlying tumour progression 
and recurrence. Nature reviews Endocrinology. 2014; 
10:455–465.
 8. Mannaa M, Kramer S, Boschmann M, Gollasch M. mTOR 
and regulation of energy homeostasis in humans. Journal of 
molecular medicine. 2013; 91:1167–1175.
 9. Makowski L, Zhou C, Zhong Y, Kuan PF, Fan C, 
Sampey BP, Difurio M, Bae-Jump VL. Obesity increases 
tumor aggressiveness in a genetically engineered mouse 
model of serous ovarian cancer. Gynecologic oncology. 
2014; 133:90–97.
10. Perl A. mTOR activation is a biomarker and a central 
pathway to autoimmune disorders, cancer, obesity, and 
aging. Annals of the New York Academy of Sciences. 2015; 
1346:33–44.
11. Sudo T. Molecular-targeted therapies for ovarian cancer: 
prospects for the future. International journal of clinical 
oncology. 2012; 17:424–429.
12. Cancer Genome Atlas Research N. Integrated genomic 
analyses of ovarian carcinoma. Nature. 2011; 474:609–615.
13. No JH, Jeon YT, Park IA, Kim YB, Kim JW, Park NH, 
Kang SB, Han JY, Lim JM, Song YS. Activation of mTOR 
signaling pathway associated with adverse prognostic 
factors of epithelial ovarian cancer. Gynecologic oncology. 
2011; 121:8–12.
14. Bunkholt Elstrand M, Dong HP, Odegaard E, Holth A, 
Elloul S, Reich R, Trope CG, Davidson B. Mammalian 
target of rapamycin is a biomarker of poor survival in 
metastatic serous ovarian carcinoma. Human pathology. 
2010; 41:794–804.
15. Diaz-Padilla I, Duran I, Clarke BA, Oza AM. Biologic rationale 
and clinical activity of mTOR inhibitors in gynecological 
cancer. Cancer treatment reviews. 2012; 38:767–775.
16. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR 
Signaling in Cancer. Frontiers in oncology. 2014; 4:64.
17. O’Reilly T, McSheehy PM. Biomarker Development for 
the Clinical Activity of the mTOR Inhibitor Everolimus 
(RAD001): Processes, Limitations, and Further Proposals. 
Translational oncology. 2010; 3:65–79.
18. Abdel-Rahman O, Fouad M. Risk of mucocutaneous 
toxicities in patients with solid tumors treated with 
everolimus; a systematic review and meta-analysis. Expert 
review of anticancer therapy. 2014; 14:1529–1536.
19. Haines DD, Juhasz B, Tosaki A. Management of 
multicellular senescence and oxidative stress. Journal of 
cellular and molecular medicine. 2013; 17:936–957.
20. Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, 
Takahashi R, Sawada K, Ito K, Kurachi H, Schilder RJ, 
Testa JR, Kimura T. Potential role of mTORC2 as a 
therapeutic target in clear cell carcinoma of the ovary. 
Molecular cancer therapeutics. 2013; 12:1367–1377.
21. Fiebrich HB, Siemerink EJ, Brouwers AH, Links TP, 
Remkes WS, Hospers GA, de Vries EG. Everolimus 
induces rapid plasma glucose normalization in insulinoma 
patients by effects on tumor as well as normal tissues. The 
oncologist. 2011; 16:783–787.
22. Dimitrakopoulou-Strauss A, Hohenberger P, Strobel P, 
Marx A, Strauss LG. A recent application of fluoro-18-
deoxyglucose positron emission tomography, treatment 
monitoring with a mammalian target of rapamycin inhibitor: 
an example of a patient with a desmoplastic small round cell 
tumor. Hellenic journal of nuclear medicine. 2007; 10:77–79.
23. Ferrer-Garcia JC, Tolosa-Torrens M, Hernando-Melia C, 
Arribas-Palomar L, Sanchez-Juan C. Everolimus 
resolving hypoglycemia, producing hyperglycemia, and 
necessitating insulin use in a patient with diabetes and 
nonresecTable malignant insulinoma. Endocrine practice. 
2011; 17:e17–20.
24. Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, 
Householder DB, Baran ML, Yi M, Song Y, Sun W, 
McDunn JE, Martin PL, Van Dyke T, et al. Perturbation 
of Rb, p53, and Brca1 or Brca2 cooperate in inducing 
metastatic serous epithelial ovarian cancer. Cancer research. 
2012; 72:4141–4153.
25. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, 
Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, 
Dong M, Phan AT, Wolff RA, Gupta S, et al. PIK3CA/
PTEN mutations and Akt activation as markers of 
sensitivity to allosteric mTOR inhibitors. Clinical cancer 
research. 2012; 18:1777–1789.
26. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, 
Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, 
Testa JR. RAD001 (Everolimus) delays tumor onset and 
progression in a transgenic mouse model of ovarian cancer. 
Cancer research. 2007; 67:2408–2413.
27. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, 
Hensley HH, Schilder RJ, Ozols RF, Testa JR. RAD001 
inhibits human ovarian cancer cell proliferation, enhances 
cisplatin-induced apoptosis, and prolongs survival in an 
ovarian cancer model. Clinical cancer research. 2007; 
13:4261–4270.
28. Deng GL, Zeng S, Shen H. Chemotherapy and target 
therapy for hepatocellular carcinoma: New advances 
and challenges. World journal of hepatology. 2015; 7: 
787–798.
Oncotarget20355www.impactjournals.com/oncotarget
29. Baraz R, Cisterne A, Saunders PO, Hewson J, Thien M, 
Weiss J, Basnett J, Bradstock KF, Bendall LJ. mTOR 
inhibition by everolimus in childhood acute lymphoblastic 
leukemia induces caspase-independent cell death. PloS one. 
2014; 9:e102494.
30. Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, 
Anderson L, O’Brien NA, Kolarova T, Finn RS, Linnartz R, 
Chen D, Slamon DJ. In vitro activity of the mTOR inhibitor 
everolimus, in a large panel of breast cancer cell lines and 
analysis for predictors of response. Breast cancer research 
and treatment. 2015; 149:669–680.
31. Schrauwen P, Westerterp KR. The role of high-fat diets 
and physical activity in the regulation of body weight. The 
British journal of nutrition. 2000; 84:417–427.
32. Santana A, Santamarina A, Souza G, Mennitti L, Okuda M, 
Venancio D, Seelaender M, Oller do Nascimento C, Ribeiro E, 
Lira F, Oyama L. Decaffeinated green tea extract rich in 
epigallocatechin-3-gallate improves insulin resistance and 
metabolic profiles in normolipidic diet-but not high-fat diet-
fed mice. The Journal of nutritional biochemistry. 2015; 
26:893–902.
33. Cho HJ, Kwon GT, Park H, Song H, Lee KW, Kim JI, Park JH. 
A high-fat diet containing lard accelerates prostate cancer 
progression and reduces survival rate in mice: possible 
contribution of adipose tissue-derived cytokines. Nutrients. 
2015; 7:2539–2561.
34. Thompson KJ, Swan RZ, Walling TL, Iannitti DA, 
McKillop IH, Sindram D. Obesity, but not ethanol, 
promotes tumor incidence and progression in a mouse 
model of hepatocellular carcinoma in vivo. Surgical 
endoscopy. 2013; 27:2782–2791.
35. Zhao Y, Tan YS, Aupperlee MD, Langohr IM, Kirk EL, 
Troester MA, Schwartz RC, Haslam SZ. Pubertal high 
fat diet: effects on mammary cancer development. Breast 
cancer research. 2013; 15:R100.
36. Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, 
Gomez SB, Ji B, Huang H, Wang H, Fleming JB, Logsdon CD, 
Cruz-Monserrate Z. A high-fat diet activates oncogenic 
Kras and COX2 to induce development of pancreatic 
ductal adenocarcinoma in mice. Gastroenterology. 2013; 
145:1449–1458.
37. Tiwari A, Ocon-Grove OM, Hadley JA, Giles JR, Johnson PA, 
Ramachandran R. Expression of adiponectin and its 
receptors is altered in epithelial ovarian tumors and ascites-
derived ovarian cancer cell lines. International journal of 
gynecological cancer. 2015; 25:399–406.
38. Maccio A, Madeddu C. Inflammation and ovarian cancer. 
Cytokine. 2012; 58:133–147.
39. Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S, 
Munkarah AR, Rattan R. Metformin limits the adipocyte 
tumor-promoting effect on ovarian cancer. Oncotarget. 
2014; 5:4746–4764. doi: 10.18632/oncotarget.2012.
40. Dier U, Shin DH, Hemachandra LP, Uusitalo LM, Hempel N. 
Bioenergetic analysis of ovarian cancer cell lines: 
profiling of histological subtypes and identification of a 
mitochondria-defective cell line. PloS one. 2014; 9:e98479.
41. Kasiappan R, Sun Y, Lungchukiet P, Quarni W, Zhang X, 
Bai W. Vitamin D suppresses leptin stimulation of cancer 
growth through microRNA. Cancer research. 2014; 
74:6194–6204.
42. Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang 
F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen 
J, Gully C, Carlock C, Qi Y, et al. Effects of obesity on 
transcriptomic changes and cancer hallmarks in estrogen 
receptor-positive breast cancer. Journal of the National 
Cancer Institute. 2014; 106.
43. Han J, Zhang L, Guo H, Wysham WZ, Roque DR, 
Willson AK, Sheng X, Zhou C, Bae-Jump VL. Glucose 
promotes cell proliferation, glucose uptake and invasion in 
endometrial cancer cells via AMPK/mTOR/S6 and MAPK 
signaling. Gynecologic oncology. 2015.
44. Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, 
Cacciatore S, Schultz D, Scaglia N, McDunn J, De Marzo AM, 
Loda M. AKT1 and MYC induce distinctive metabolic 
fingerprints in human prostate cancer. Cancer research. 
2014; 74:7198–7204.
45. McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, 
Milburn MV, Lotan Y, Wheeler TM. Metabolomic 
signatures of aggressive prostate cancer. The Prostate. 2013; 
73:1547–1560.
46. Lewis JR, O’Brien TG, Skorupski KA, Krick EL, Reiter AM, 
Jennings MW, Jurney CH, Shofer FS. Polyamine inhibitors 
for treatment of feline oral squamous cell carcinoma: a 
proof-of-concept study. Journal of veterinary dentistry. 
2013; 30:140–145.
47. Tierny D, Serres F, Segaoula Z, Bemelmans I, Bouchaert E, 
Petain A, Brel V, Couffin S, Marchal T, Nguyen L, Thuru X, 
Ferre P, Guilbaud N, et al. Phase 1 clinical pharmacology 
study of F14512, a new polyamine-vectorized anti-cancer 
drug, in naturally occurring canine lymphoma. Clinical 
cancer research. 2015.
48. Poisson LM, Munkarah A, Madi H, Datta I, Hensley-Alford S, 
Tebbe C, Buekers T, Giri S, Rattan R. A metabolomic 
approach to identifying platinum resistance in ovarian 
cancer. Journal of ovarian research. 2015; 8:13.
49. van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-
Bosscha H, Schroder CP, Pot L, Kosterink JG, van der 
Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, 
Reyners AK. Measurement of tumor VEGF-A levels with 
89Zr-bevacizumab PET as an early biomarker for the 
antiangiogenic effect of everolimus treatment in an ovarian 
cancer xenograft model. Clinical cancer research. 2012; 
18:6306–6314.
50. Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, 
Ronen SM. Hyperpolarized 13C MR spectroscopic imaging 
can be used to monitor Everolimus treatment in vivo in an 
orthotopic rodent model of glioblastoma. NeuroImage. 2012; 
59:193–201.
Oncotarget20356www.impactjournals.com/oncotarget
51. Devaraj S, Hemarajata P, Versalovic J. The human gut 
microbiome and body metabolism: implications for obesity 
and diabetes. Clinical chemistry. 2013; 59:617–628.
52. Corda D, Mosca MG, Ohshima N, Grauso L, Yanaka N, 
Mariggio S. The emerging physiological roles of the 
glycerophosphodiesterase family. The FEBS journal. 2014; 
281:998–1016.
53. Stewart JD, Marchan R, Lesjak MS, Lambert J, 
Hergenroeder R, Ellis JK, Lau CH, Keun HC, Schmitz G, 
Schiller J, Eibisch M, Hedberg C, Waldmann H, et al. 
Choline-releasing glycerophosphodiesterase EDI3 drives 
tumor cell migration and metastasis. Proceedings of the 
National Academy of Sciences of the United States of 
America. 2012; 109:8155–8160.
54. Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, 
Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, 
Copeland RL, Sr., Gabrielson E, et al. Metabolic profile of 
triple-negative breast cancer in African-American women 
reveals potential biomarkers of aggressive disease. Cancer 
genomics & proteomics. 2014; 11:279–294.
55. Abramov Y, Carmi S, Anteby SO, Ringel I. Ex vivo 1H 
and 31P magnetic resonance spectroscopy as a means for 
tumor characterization in ovarian cancer patients. Oncology 
reports. 2013; 29:321–328.
56. Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, 
Shinohara K, Vigneron DB, Kurhanewicz J. Correlation of 
phospholipid metabolites with prostate cancer pathologic 
grade, proliferative status and surgical stage - impact of 
tissue environment. NMR in biomedicine. 2011; 24:691–699.
57. Hutschenreuther A, Birkenmeier G, Bigl M, Krohn K, 
Birkemeyer C. Glycerophosphoglycerol, Beta-alanine, and 
pantothenic Acid as metabolic companions of glycolytic 
activity and cell migration in breast cancer cell lines. 
Metabolites. 2013; 3:1084–1101.
58. Koldehoff M, Beelen DW, Elmaagacli AH. Inhibition 
of mTOR with everolimus and silencing by vascular 
endothelial cell growth factor-specific siRNA induces 
synergistic antitumor activity in multiple myeloma cells. 
Cancer gene therapy. 2014; 21:275–282.
59. Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, 
Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H. Aberrant 
activation of the mTOR pathway and anti-tumour effect of 
everolimus on oesophageal squamous cell carcinoma. British 
journal of cancer. 2012; 106:876–882.
60. Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, 
Amornphimoltham P, Nathan CA, Singh B, Weigert R, 
Molinolo AA, Gutkind JS. Decreased lymphangiogenesis 
and lymph node metastasis by mTOR inhibition in head and 
neck cancer. Cancer research. 2011; 71:7103–7112.
61. Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, 
Tsaur I, Wiesner C, Haferkamp A, Blaheta RA. Impact 
of combined HDAC and mTOR inhibition on adhesion, 
migration and invasion of prostate cancer cells. Clinical & 
experimental metastasis. 2011; 28:479–491.
62. Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, 
Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, 
Rich JN. The combination of novel low molecular weight 
inhibitors of RAF (LBT613) and target of rapamycin 
(RAD001) decreases glioma proliferation and invasion. 
Molecular cancer therapeutics. 2007; 6:2449–2457.
63. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I. Emergent 
toxicities associated with the use of mTOR inhibitors in 
patients with advanced renal carcinoma. Anti-cancer drugs. 
2010; 21:478–486.
64. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, 
Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Metabolic 
complications with the use of mTOR inhibitors for cancer 
therapy. Cancer treatment reviews. 2014; 40:190–196.
65. Grunwald V, Weikert S, Pavel ME, Horsch D, Luftner D, 
Janni W, Geberth M, Weber MM. Practical management of 
everolimus-related toxicities in patients with advanced solid 
tumors. Onkologie. 2013; 36:295–302.
66. Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, 
Papazisis K, Porta C, Pritchard K, Ravaud A. Adverse event 
management in patients with advanced cancer receiving 
oral everolimus: focus on breast cancer. Annals of oncology. 
2014; 25:763–773.
67. Lawton KA, Berger A, Mitchell M, Milgram KE, 
Evans AM, Guo L, Hanson RW, Kalhan SC, Ryals JA, 
Milburn MV. Analysis of the adult human plasma 
metabolome. Pharmacogenomics. 2008; 9:383–397.
68. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, 
Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. 
Profiling the effects of isocitrate dehydrogenase 1 and 2 
mutations on the cellular metabolome. Proc Natl Acad Sci 
U S A. 2011; 108:3270–3275.
69. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. 
Integrated, nontargeted ultrahigh performance liquid 
chromatography/electrospray ionization tandem mass 
spectrometry platform for the identification and relative 
quantification of the small-molecule complement of biological 
systems. Analytical chemistry. 2009; 81:6656–6667.
70. Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, 
Troester MA, Macintyre AN, Goraksha-Hicks P, 
Rathmell JC, Makowski L. Metabolic reprogramming 
of macrophages: glucose transporter (GLUT1)-mediated 
glucose metabolism drives a pro- inflammatory phenotype. 
The Journal of biological chemistry. 2014.
